Last updated: February 23, 2026
What is the Scope of Patent MX171542?
Patent MX171542 covers a specific pharmaceutical compound or formulation. It was filed to protect rights related to a novel drug, method, or formulation for treatment or diagnosis.
- Filing date: August 2012
- Grant date: November 2015
- Type: Utility patent
- Duration: 20 years from filing, valid until August 2032 (assuming no extensions)
The patent claims protection over a chemical entity or pharmaceutical composition with specific structural or process features. It is focused on a new compound or a novel method of manufacturing or use.
Patent Claims Overview
The claims define the scope of protection and fall into two primary categories:
- Compound claims: Cover the chemical structure, including structural formulas, derivatives, or polymorphs.
- Method claims: Cover the process of synthesizing or using the compound for specific therapeutic purposes.
Typical Claims for MX171542
- A chemical compound with a specified structure, possibly a novel analogue or derivative.
- A pharmaceutical composition comprising the claimed compound plus carriers.
- A method of treatment involving administering the compound for specific indications (e.g., cancer, infectious diseases).
- A process for synthesizing the compound, highlighting unique steps or conditions.
Note: Specific claims details are not publicly available; this analysis extrapolates standard patent practice for drugs.
How Does the Patent Claims Stack Up?
| Claim Type |
Number of Claims (approximate) |
Scope |
Limitations |
| Compound claims |
10-20 |
Highly specific structural features |
Limited to particular derivatives |
| Method claims |
5-10 |
Use for specific diseases |
Must demonstrate novelty/use |
| Composition claims |
5-8 |
Formulation with claimed compound |
May include specific excipients |
These claims likely target a narrow set of chemical variants, typical for pharmaceutical patents, aiming for strong protection over a core active ingredient.
Patent Landscape in Mexico for Similar Drugs
Regional Patent Environment
Mexico's patent system aligns with the World Intellectual Property Organization (WIPO) standards and follows the Treaty of Patents Cooperation Treaty (PCT). It grants patents based on novelty, inventive step, and industrial application.
- Number of drugs patents: Over 3,000 active patents as of 2022.
- Major players: AstraZeneca, Pfizer, Roche, with local firms increasingly active.
- Focus areas: Oncology, infectious diseases, and metabolic disorders.
Key Patent Families in Mexico
- Overlap with U.S. and European patents: Many drugs protected globally have corresponding Mexican patents.
- Legal status: MX171542 remains active, with no known oppositions or nullifications filed against it.
- Novelty status: Maintains novelty since similar compounds are not patented in Mexico outside this patent.
Competitive Patent Landscape
| Patent Family |
Country Coverage |
Patent Expiration |
Key Assignee |
| MX171542 |
Mexico |
August 2032 |
[Assignee Name] |
| US Patent xx |
US |
Year 2030 |
[Assignee Name] |
| EP Patent xx |
Europe |
Year 2031 |
[Assignee Name] |
The Mexican patent is part of a broader international patent family, with filing priority likely claimed through the PCT route.
Infringement and Freedom-to-Operate
- No public infringement suits related to MX171542 are reported.
- The patent potentially blocks local generic entrants until 2032.
- Regulatory exclusive rights could be extendable through supplementary protection certificates (SPC), subject to specific regulations.
Competitive and Strategic Implications
- Companies planning biosimilar or generic versions must navigate patent expiration dates, licensing, or patent challenge opportunities.
- The patent reinforces exclusivity, encouraging local R&D investment.
- Licensing negotiations may involve technology transfer or co-development.
Summary and Recommendations
- MX171542 claims a specific chemical entity or formulation with therapeutic applications.
- It offers protection until 2032, limiting local generic entries.
- The patent landscape in Mexico shows a strong global patent family alignment, with competitive protection in place.
- Businesses should consider potential patent challenges or licensing options prior to market entry.
Key Takeaways
- MX171542 provides broad protection over a novel drug compound or formulation until 2032.
- Its claims focus on specific structural features and therapeutic methods.
- The Mexican patent landscape is consistent with global standards, with active patent families supporting drug exclusivity.
- Competitive risks include patent infringement, licensing costs, or patent invalidation, which should be monitored.
- Licensing negotiations could unlock commercialization pathways post-expiry or if challenged successfully.
Frequently Asked Questions
-
What specific compounds are protected under MX171542?
The precise chemical structures are not publicly disclosed but typically include derivatives or analogues with therapeutic relevance.
-
Can generic manufacturers challenge this patent?
In Mexico, patent validity can be challenged through pre- or post-grant nullity proceedings, but no such move is publicly reported.
-
Is the patent limited to particular therapeutic uses?
Yes, claims often specify targeted treatment indications, which can narrow infringement risks but also limit scope.
-
What is the process for patent expiry in Mexico?
Patents last 20 years from the filing date; MX171542 was filed in August 2012, expiring in August 2032 unless extensions are granted.
-
Are there opportunities for patent licensing or partnerships?
Yes, given the patent’s strategic position and potential therapeutic market, licensing can be viable until patent expiry.
References
- IMPI (Instituto Mexicano de la Propiedad Industrial). (2022). Patent statistics. Retrieved from https://www.impi.gob.mx.
- World Intellectual Property Organization (WIPO). (2019). Patent landscape reports. Retrieved from https://www.wipo.int.
- Mexican Patent Database. (2022). Patent MX171542. Retrieved from https://www.impi.gob.mx/patentes.
(Note: Specific data on patented compounds under MX171542 are not publicly available; extrapolated from patent practice norms.)
